GB-0998
Phase 3Small molecule
GB-0998 is one of 113 small molecule programs targeting Miscarriage. It is currently in Phase 3.
3
Indications
5
Total Trials
0
Active Trials
112
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
102 competitors in Myasthenia Gravis
#DrugCompanyPhaseTrials
1Rituxan
RochePhase 3
Ultomiris
AstraZenecaPhase 3
Vyvgart
ArgenxPhase 3
Cellcept
RochePhase 3
Soliris
AstraZenecaPhase 3
Zilbrysq
UCBPhase 3
Fabhalta
Johnson & JohnsonPhase 3
Arava
SanofiPhase 3
ENSPRYNG
RochePhase 3
Rhapsido
NovartisPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Desensitization1 trial
Dermatomyositis1 trial
Miscarriage1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for GB-0998. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details